Compare Trump Media and Technology Group Corp (DJT) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs Gilead Sciences, Inc. — how do they compare? Trump Media and Technology Group Corp trades at $8.09 (market cap $2.28B), while Gilead Sciences, Inc. trades at $150.84 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 80× Trump Media and Technology Group Corp's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Gilead Sciences, Inc. for 111 Days on average.
| DJT | GILD | |
|---|---|---|
Market Cap | $2.28B | $182.40B |
Volume | 3,148,379 | 4,469,821 |
Sector | Media | Health |
52-Week High | $17.07 | $155.80 |
52-Week Low | $7.06 | $116.74 |
Typical Hold Time | 17 Days | 111 Days |
Enterprise Value | $2.35B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.125, down 1.16% with a bearish technical signal. The company shows minimal revenue of $3.68M against massive losses of -$712M, resulting in a negative net margin of -28,860%. Cash flow trends reveal heavy investing outflows, while a proposed merger with TAE Technologies aims to pivot toward fusion energy development. The stock faces significant fundamental challenges despite oversold RSI indicators.
Outlook remains highly speculative with substantial execution risks. The merger could provide long-term upside if fusion technology commercializes, but current financials and negative profitability signal extreme caution. Investors face dilution risk and cash burn with no near-term profit visibility.
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
